Acumen Pharmaceuticals (NASDAQ: ABOS) CFO sells shares to cover taxes

Rhea-AI Filing Summary

Acumen Pharmaceuticals, Inc. executive stock activity: CFO & Chief Business Officer Matt Zuga reported several sales of Acumen common stock. On January 5, 2026, he sold 4,000 shares at a weighted average price of $1.9606. On January 6, 2026, he sold 5,100 shares at a weighted average price of $1.9662. On January 7, 2026, he sold 4,105 shares at a weighted average price of $1.995 and an additional 1,700 shares at a weighted average price of $1.9862. Footnotes explain that the 4,000- and 1,700-share sales were automatic “sell to cover” transactions to satisfy tax withholding on vesting RSUs under Rule 10b5-1 trading plans adopted on August 30, 2024 and June 30, 2025. After these transactions, he beneficially owned 216,839 shares of Acumen common stock directly.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Zuga Matt

(Last) (First) (Middle)

C/O ACUMEN PHARMACEUTICALS, INC.

1210-1220 WASHINGTON STREET, SUITE 210

(Street)

NEWTON MA 02465

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Acumen Pharmaceuticals, Inc. [ ABOS ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	CFO & Chief Business Officer

3. Date of Earliest Transaction (Month/Day/Year)
01/05/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	01/05/2026		S		4,000(1)	D	$1.9606(2)	227,744	D
Common Stock	01/06/2026		S		5,100(1)	D	$1.9662(3)	222,644	D
Common Stock	01/07/2026		S		4,105(1)	D	$1.995(4)	218,539	D
Common Stock	01/07/2026		S		1,700(5)	D	$1.9862(6)	216,839	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents the number of shares sold by the Reporting Person through an automatic "sell to cover" transaction to satisfy tax withholding obligations in connection with the vesting of restricted stock units ("RSUs") pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 30, 2024.

2. The price reported is a weighted average sales price. The shares were sold in multiple transactions at prices ranging from $1.9100 to $1.9750. Upon request, the Reporting Person will provide to the staff of the Securities and Exchange Commission, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

3. The price reported is a weighted average sales price. The shares were sold in multiple transactions at prices ranging from $1.9400 to $1.9900. Upon request, the Reporting Person will provide to the staff of the Securities and Exchange Commission, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

4. The price reported is a weighted average sales price. The shares were sold in multiple transactions at prices ranging from $1.9500 to $2.0400. Upon request, the Reporting Person will provide to the staff of the Securities and Exchange Commission, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

5. Represents the number of shares sold by the Reporting Person through an automatic "sell to cover" transaction to satisfy tax withholding obligations in connection with the vesting of RSUs pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 30, 2025.

6. The price reported is a weighted average sales price. The shares were sold in multiple transactions at prices ranging from $1.9600 to $2.0100. Upon request, the Reporting Person will provide to the staff of the Securities and Exchange Commission, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Remarks:

	/s/ Derek Meisner, Attorney-in-Fact	01/07/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

Who is the insider in Acumen Pharmaceuticals (ABOS) latest Form 4?

The insider is Matt Zuga, who serves as CFO & Chief Business Officer of Acumen Pharmaceuticals, Inc.

How many Acumen (ABOS) shares did the CFO sell in January 2026?

Across January 5–7, 2026, CFO Matt Zuga reported sales of 4,000, 5,100, 4,105, and 1,700 shares of Acumen common stock in separate transactions.

At what prices were the Acumen (ABOS) shares sold by the CFO?

The reported weighted average sale prices were $1.9606, $1.9662, $1.995, and $1.9862 per share, each representing multiple trades within stated price ranges.

Why did the Acumen (ABOS) CFO sell shares according to the Form 4 footnotes?

The footnotes state that the 4,000- and 1,700-share transactions were automatic “sell to cover” sales to satisfy tax withholding obligations related to vesting RSUs under Rule 10b5-1 trading plans.

What Rule 10b5-1 trading plans are mentioned in the Acumen (ABOS) Form 4?

The Form 4 notes Rule 10b5-1 trading plans adopted by the reporting person on August 30, 2024 and June 30, 2025 in connection with RSU vesting and tax withholding.

How many Acumen (ABOS) shares does the CFO own after these transactions?

Following the reported sales, CFO Matt Zuga beneficially owned 216,839 shares of Acumen Pharmaceuticals common stock directly.

Are the Acumen (ABOS) CFO’s January 2026 stock sales direct or indirect holdings?

The transactions are reported as direct (D) ownership, with no nature of indirect beneficial ownership indicated.